We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+25.89%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.2B
AUM Growth
+$101M
Cap. Flow
-$127M
Cap. Flow %
-10.58%
Top 10 Hldgs %
84.52%
Holding
38
New
5
Increased
5
Reduced
6
Closed
6

Top Buys

Rank Stock Value
1
SPRY icon
ARS Pharmaceuticals
SPRY
+$23M
2
TEM
Tempus AI
TEM
+$20.6M
3
INCY icon
Incyte
INCY
+$7.9M
4
UNH icon
UnitedHealth
UNH
+$7.56M
5
GPCR icon
Structure Therapeutics
GPCR
+$6.57M

Top Sells

Rank Stock Value
1
WGS icon
GeneDx Holdings
WGS
+$54.5M
2
VERV
Verve Therapeutics
VERV
+$46M
3
BLFS icon
BioLife Solutions
BLFS
+$23.7M
4
CDXS icon
Codexis
CDXS
+$17.6M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$16.9M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CTNM
26
Contineum Therapeutics
CTNM
$599M
$1.74M 0.15%
148,333
– –
PACB icon
27
Pacific Biosciences
PACB
$441M
$926K 0.08%
723,767
– –
RXRX icon
28
Recursion Pharmaceuticals
RXRX
$1.69B
$807K 0.07%
165,323
– –
GLUE icon
29
Monte Rosa Therapeutics
GLUE
$1.3B
$637K 0.05%
86,014
– –
IPSC icon
30
Century Therapeutics
IPSC
$357M
$612K 0.05%
1,228,190
– –
TNYA icon
31
Tenaya Therapeutics
TNYA
$158M
$586K 0.05%
361,969
– –
DNA icon
32
Ginkgo Bioworks
DNA
$584M
$532K 0.04%
36,493
– –
AGIO icon
33
Agios Pharmaceuticals
AGIO
$1.82B
– –
-100,000
Closed -$3.33M
CDXS icon
34
Codexis
CDXS
$156M
– –
-7,200,000
Closed -$17.6M
LLY icon
35
Eli Lilly
LLY
$1,000B
– –
-8,500
Closed -$6.63M
SNDX icon
36
Syndax Pharmaceuticals
SNDX
$1.7B
– –
-650,000
Closed -$6.08M
SRPT icon
37
Sarepta Therapeutics
SRPT
$1.68B
– –
-990,097
Closed -$16.9M
VERV
38
DELISTED
Verve Therapeutics
VERV
– –
-4,095,571
Closed -$46M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q3 2025 Portfolio in Review

As of Q3 2025, Casdin Capital held 38 positions worth $1.2B, up 9.2% from $1.1B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Casdin Capital withdrew a net $127M in Q3 2025, closing 6 positions and reducing 6 holdings. Its most notable exit was Verve Therapeutics, an estimated $46M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Casdin Capital opened a new position in ARS Pharmaceuticals worth $16.1M.

  • Casdin Capital's largest Q3 2025 buy was ARS Pharmaceuticals: 1,600,000 shares worth $16.1M.
  • Casdin Capital added most to Structure Therapeutics in Q3 2025, an estimated $6.57M increase.
  • Casdin Capital's biggest Q3 2025 reduction was GeneDx Holdings, cutting an estimated $54.5M.
  • Casdin Capital fully exited Verve Therapeutics in Q3 2025, selling an estimated $46M.
  • Casdin Capital's ten largest holdings make up 85% of its $1.2B portfolio in Q3 2025.
  • Casdin Capital opened 5 new positions and closed 6 in Q3 2025.
  • Casdin Capital's portfolio value rose 9.2% quarter-over-quarter to $1.2B.

Based on Casdin Capital's 13F filing for Q3 2025, filed 14 Nov 2025.